Investigation of the Impact of Radial Wall Strain at Coronary Stent Edges on Edge Restenosis After Percutaneous Coronary Intervention

Investigation of the Impact of Radial Wall Strain at Coronary Stent Edges on Edge Restenosis After Percutaneous Coronary Intervention - Investigation of the Impact of Radial Wall Strain at Coronary Stent Edges on Edge Restenosis After Percutaneous Coronary Intervention

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056799

Enrollment

1300

Registered

2025-04-01

Start date

2025-03-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who underwent PCI using second-generation or later DES for untreated lesions 2) Patients who underwent follow-up CAG at least one month after PCI 3) Patients aged 20 years or older at the time of PCI

Exclusion criteria

Exclusion criteria: 1) Lesions where RWS measurement is challenging 2) Proximal stent edges of lesions where DES is implanted in the coronary ostium 3) Lesions located in vessels that underwent bypass surgery 4) Lesions where DES is implanted in graft vessels 5) Lesions showing coronary dissection on the final angiography during PCI 6) Lesions located in small vessels with a diameter of 2 mm or less 7) Lesions showing more than 50% stenosis at stent edges on the final angiography during PCI

Design outcomes

Primary

Measure	Time frame
RWS values at stent edges on post-pci cag in stent edge restenotic and non-restenotic lesions	—

Secondary

Measure	Time frame
1) RWS values at stent edges on post-PCI CAG in clinical stent edge restenotic and non-restenotic lesions 2) RWS values at stent edges on pre-PCI CAG in stent edge restenotic and non-restenotic lesions 3) Target Lesion Revascularization (TLR) 4) Target Vessel Revascularization (TVR) 5) Culprit Lesion-Related Major Adverse Cardiac Events (CL-MACE) 6) Stent Edge-Related Major Adverse Cardiac Events (Stent Edge-Related MACE) 7) In-Stent Segment-Related Major Adverse Cardiac Events (In-Stent Segment-Related MACE) 8) Cardiac Death	—

Measure

Time frame

1) RWS values at stent edges on post-PCI CAG in clinical stent edge restenotic and non-restenotic lesions 2) RWS values at stent edges on pre-PCI CAG in stent edge restenotic and non-restenotic lesions 3) Target Lesion Revascularization (TLR) 4) Target Vessel Revascularization (TVR) 5) Culprit Lesion-Related Major Adverse Cardiac Events (CL-MACE) 6) Stent Edge-Related Major Adverse Cardiac Events (Stent Edge-Related MACE) 7) In-Stent Segment-Related Major Adverse Cardiac Events (In-Stent Segment-Related MACE) 8) Cardiac Death

—

Countries

Japan

Contacts

Public ContactKen Takata

Kobe University Hospital Department of Cardiovascular Medicine

forestwwood13@gmail.com078-382-5846

Outcome results